Information Provided By:
Fly News Breaks for July 3, 2019
Jul 3, 2019 | 06:40 EDT
RBC Capital analyst Randall Stanicky kept his Outperform rating and $184 price target on Jazz Pharmaceuticals after his discussions with the company detailing its launch plans and commercial landscape for Sunosi which received a Schedule IV designation last month. The analyst notes that while only a limited contribution is expected from the program this year, the company forecast a "more bullish peak outlook than expected" at over $500M in the US.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ